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Abstract
Evidence on the association between vitamin D status and pancreatic cancer risk is incon-
sistent. This inconsistency may be partially attributable to variation in vitamin D regulating
genes. We selected 11 vitamin D-related genes (GC, DHCR7, CYP2R1, VDR, CYP27B1,
CYP24A1, CYP27A1, RXRA, CRP2, CASR and CUBN) totaling 213 single nucleotide poly-
morphisms (SNPs), and examined associations with pancreatic adenocarcinoma. Our
study included 3,583 pancreatic cancer cases and 7,053 controls from the genome-wide as-
sociation studies of pancreatic cancer PanScans-I-III. We used the Adaptive Joint Test and
the Adaptive Rank Truncated Product statistic for pathway and gene analyses, and uncon-
ditional logistic regression for SNP analyses, adjusting for age, sex, study and population
stratification. We examined effect modification by circulating vitamin D concentration (50,
>50 nmol/L) for the most significant SNPs using a subset of cohort cases (n = 713) and con-
trols (n = 878). The vitamin D metabolic pathway was not associated with pancreatic cancer
risk (p = 0.830). Of the individual genes, none were associated with pancreatic cancer risk
at a significance level of p<0.05. SNPs near the VDR (rs2239186), LRP2 (rs4668123),
CYP24A1 (rs2762932),GC (rs2282679), and CUBN (rs1810205) genes were the top SNPs
associated with pancreatic cancer (p-values 0.008–0.037), but none were statistically signif-
icant after adjusting for multiple comparisons. Associations between these SNPs and pan-
creatic cancer were not modified by circulating concentrations of vitamin D. These findings
do not support an association between vitamin D-related genes and pancreatic cancer risk.
Future research should explore other pathways through which vitamin D status might be as-
sociated with pancreatic cancer risk.
Introduction
Vitamin D signaling is of interest in relation to cancer because of its hypothesized role in in-
ducing immune cell differentiation and inhibiting tumor proliferation and angiogenesis [1]. In
humans, most vitamin D is synthesized endogenously via exposure of the skin to solar ultra-vi-
olet B radiation, which converts 7-dehyrocholesterol in skin to vitamin D. Small amounts
come also from dietary sources such as fish or fortified dairy products and, in some popula-
tions, dietary supplements [2].
Some previous studies have suggested lower pancreatic cancer risk with proxy markers of
higher vitamin D status. Ecologic studies, which are based on population averages rather than
individual level data, have shown lower pancreatic cancer death rates in areas with more sun
exposure in Spain [3], the United States [4,5], and Japan [6,7]. A large, prospective study that
used a predicted estimate of vitamin D status based on five determinants of serum 25-hydroxy-
vitamin D (25(OH)D) (dietary and supplemental vitamin D, skin pigmentation, adiposity, geo-
graphic residence, and leisure activity) also found an inverse association with pancreatic cancer
risk [8].
Serum 25(OH)D is the most widely used biomarker to assess vitamin D status in epidemio-
logic studies as it reflects both endogenous synthesis and dietary vitamin D intake [9]. Howev-
er, previous studies evaluating measured circulating 25(OH)D concentrations with risk of
pancreatic cancer show conflicting results. A large, pooled study of serum concentrations from
eight cohorts as part of the Vitamin D Pooling Project (952 cases, 1,333 controls) reported
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increased pancreatic cancer risk with higher circulating vitamin D concentrations (odds ratio
(OR) = 2.12, 95% confidence interval (CI)) comparing serum levels100 nmol/L to the refer-
ent 50–75nmol/L [10]. In contrast, a nested case-control study pooling five prospective cohorts
(451 cases, 1,167 controls) suggested an inverse association OR = 0.67, 95% CI 0.46–0.97 com-
paring plasma 25(OH)D quintiles (>81.05 to<45.64 nmol/L) and no association when using
the categories employed in the Vitamin D Pooling Project [11].
Pathway-based analysis of GWAS can detect associations that might be missed by focusing
on single loci or even genes [12]. To our knowledge only one previous population based case-
control study (628 cases, 1,193 controls) evaluated associations between genetic variants related
to vitamin D and pancreatic cancer, and reported no single-nucleotide polymorphism (SNP)
associations after adjustment for multiple comparisons [13]. In the present study, we used data
from 20 studies in PanScans I-III to examine 11 genes in the vitamin D metabolic pathway and
213 corresponding SNPs with risk of pancreatic cancer. In a subset of the cohorts we assessed
effect measure modification by circulating vitamin D concentrations. Some of the samples used
in this analysis overlap with those utilized in the Vitamin D Pooling Project [10]. We hypothe-
sized that the contradictory evidence on circulating vitamin D and risk of pancreatic cancer
might be explained by genetic variations in vitamin D-related genes and multiplicative interac-
tion between circulating vitamin D and genetic variation.
Materials and Methods
Study Participants
We obtained data from the 20 studies in the PanScan collaboration who agreed to participate
in this pathway analysis. PanScan phases I-III have been previously described [14–16]. Our pri-
mary analysis included genotype data from 10 cohort studies and 10 case control studies in the
PanScan collaboration. Participating cohorts included the Agricultural Health Study, Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), Give us a Clue to Cancer and
Heart Disease Study (CLUE II), Cancer Prevention Study II (CPS-II), Melbourne Collaborative
Cohort Study (MCCS), Multiethnic Cohort (MEC), New York University Women’s Health
Study (NYU-WHS), Prostate Lung Colorectal and Ovarian Cancer Screening Trial (PLCO), Se-
lenium and Vitamin E Cancer Prevention Trial (SELECT) and the VITamins and Lifestyle co-
hort (VITAL). The included case-control studies were the Mayo Clinic Molecular
Epidemiology of Pancreatic Cancer Study, University of California San Francisco, Yale Univer-
sity, MD Anderson Cancer Center, University of Toronto, Johns Hopkins University, Memori-
al Sloan-Kettering Cancer Center, PACIFIC Study of Group Health and Northern California
Kaiser Permanente, Spanish Pancreatic Cancer Study (PANKRAS II) [17], and PANcreatic
Disease ReseArch (PANDoRA) (Heidelberg, Germany) [18]. All cases were diagnosed with pri-
mary pancreatic adenocarcinoma (ICD-O-3 code C250-C259 or C25.0-C25.3, C25.7-C25.9).
In short, PanScans-I and II used a nested case-control study design for the cohort studies. Co-
hort cases were confirmed through cancer registries, death certificates or review of medical rec-
ords by medical personnel. Cohort controls for PanScan-I were incidence density sampled
with a 1:1 ratio and were alive and cancer free at the time of diagnosis of the matched case. In
all case-control studies, matching criteria included calendar year of birth within five years, gen-
der, race and ethnicity, while some cohorts also matched on age at baseline or blood draw,
smoking, date/time of blood draw, fasting status at time of blood draw, and length of follow-
up. All data was de-identified before genotyping and before samples were sent to NCI. Geno-
typing was performed at the National Cancer Institute’s (NCI’s) Cancer Genomics Research
Laboratory (formerly known as the Core Genotyping Facility) using the Illumina Human-
Hap550 array for PanScan-I, the Illumina Human 610-Quad array for PanScan II, and the
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Illumina Human 770-Quad chip for PanScan III. In PanScan III controls were previously geno-
typed using second-generation Illumina SNP microarrays (e.g. OmniExpress, Omni 1M or
Omni 2.5M) and drawn from PanScan III prospective cohorts and a Spanish case-control
study and thus were not matched to the cases [19]. SNPs reported here were limited to those
with minor allele frequencies (MAF)5%. In total, we used data from 3,583 pancreatic cancer
cases and 7,053 controls (1,108 cases and 4,353 controls from the cohorts and 2,475 cases and
2,700 controls from case-control studies) of European descent. The age and sex distribution of
cases and controls is described in S1 Table. Written consent was obtained from all study partic-
ipants. Each participating study was reviewed and approved by their local IRB for appropriate-
ness in PanScan participation (S2 Table) [15].
Vitamin D measurement
A subset of the cohort participants with GWAS data also had 25(OH)D measured in serum as
part of the Vitamin D Pooling Project (713 cases and 878 controls) [20]. These subjects were
from the following cohorts: ATBC, CLUE-II, CPS-II, NYU-WHS, and PLCO. Methods for as-
saying 25(OH)D have been previously described [10]. In short, Heartland Assays, Inc. (Ames,
Iowa) performed assays for 25(OH)D for samples from CLUE-II, CPS-II, NYU-WHS, PLCO,
and a subset of ATBC samples using the DiaSorin LIAISON 25 OH Vitamin D TOTAL Assay
(Diasorin, Inc., Stillwater, Minnesota). The remaining ATBC samples were assayed previously
using a similar method in the laboratory of Dr. R. Vieth [21]. The methods and coefficients of
variation percentages for the blinded quality control samples of the Heartland 25(OH)D mea-
sures have been previously reported (10). Using a nested components of variance analysis with
logarithmically transformed quality control measures across batches, the overall intra- and
interbatch coefficients of variation were 16.5% and 4.7% for the previously assayed concentra-
tions in the ATBC and PLCO studies, respectively.
Vitamin D-related functions of included genes
DHCR7 (DHC-7 reductase) converts pro-vitamin D3 (7-dehydrocholesterol) in the skin to
cholesterol. Alternatively, pre-vitamin D is formed from 7-dehydrocholestrol following dermal
UVB exposure. Vitamin D is also derived from diet or supplements in the form of cholecalcif-
erol (D3) or ergocalciferol (D2). The vitamin D binding protein (DBP, also known as GC),
transports provitamin D to the liver, as well as other vitamin D compounds to target tissues. In
the liver 25-hydroxylases CYP2R1 and CYP27A1 convert vitamins D2 and D3 from diet and
sun exposure to 25(OH)D (calcidiol), the major circulating vitamin D metabolite. Calcidiol is
then converted to the active form 1,25(OH)2D3 (calcitriol) by 1α-hydroxylase (CYP27B1) in
the kidney and other organs. 1α-hydroxylase (CYP27B1) is localized on the inner mitochondri-
al membrane where it produces the active form of vitamin D which binds the vitamin D recep-
tor (VDR) with substantially higher affinity than 25(OH)D. The vitamin D binding protein,
GC, transports vitamin D metabolites to target organs, where calcitriol binds to VDR and
forms a heterodimer with RXRA (retinoid x-receptor alpha). This heterodimer attaches to vita-
min D response elements on various target genes, some of which are thought to have anti-car-
cinogenic properties [1]. Vitamin D is catabolized by 24-hydroxylase (CYP24A1) to inactive
forms [22].
Three additional genes, cubulin (CUBN), megalin (LRP2) and Calcium Sensing Receptor
(CASR) were added to our analysis to be consistent with the previous study on vitamin D-relat-
ed genes and pancreatic cancer [13]. Both cubulin and megalin are plasma membrane receptors
that in combination mediate an endocytic update of GC-bound vitamin D. The CASR
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membrane protein binds calcium in the extracelluar matrix and plays an important role in
calcium homeostasis.
In total, genotype data from 213 tag SNPs with MAF> 0.05 in 11 genes involved in the syn-
thesis (DHCR7, CYP27A1, CYP2R1), transport (GC, CASR), metabolism (CYP27B1, LRP2,
CUBN), signal transduction (VDR, RXRA) or catabolism (CYP24A1) of endogenous vitamin
D were used in our analysis [1]. These SNPs are located within a span of 20kb 50 upstream
and 10kb 30 downstream of the gene coding region as defined by the National Center for Bio-
technology Information’s human genome build 36.3. SNPs and associated genes are listed in
S3 Table.
Statistical analysis
We used unconditional logistic regression to test the association between individual SNPs and
pancreatic cancer risk, adjusting for age (50, 51–60, 61–70, 71–80,81 years), sex, study, and
5 eigenvectors capturing ethnic ancestry. We performed the pathway and gene analyses using
the R package AdaJoint and the adaptive rank truncated product (ARTP) statistic [23]. In each
analysis 1,000,000 permutations were conducted. This statistic accounts for gene or pathway
size and linkage disequilibrium and summarizes joint association signals within a gene or path-
way. Analyses were restricted to Caucasians. We also tested for heterogeneity between the
three phases (PanScan I, PanScan II and PanScan III) using the R package for fixed effects
meta-analysis. We adjusted for multiple comparisons in the p-heterogeneity analysis consider-
ing a p-value<0.0002 as significant. Analyses stratified by the three PanScan phases were per-
formed to explore possible differences in associations by phase.
To test possible effect modification by vitamin D status, we performed stratified analyses in
the subset of cohort studies with measured 25(OH)D; we created a dichotomous variable for
circulating vitamin D (50 nmol/L or>50 nmol/L), as above this threshold is considered to be
adequate for bone and overall health in national recommendations [24,25] and was close to the
median for controls in our study population (control median 25(OH)D = 51.5 nmol/L). In this
subset analysis we additionally adjusted for smoking (never, former, current), body mass index
(BMI), and season of blood draw (fall, winter, spring, summer). To test for multiplicative inter-
action, we created an interaction term between circulating vitamin D as a dichotomous variable
and individual SNPs. Using a Bonferroni correction for multiple comparisons, genes with a p-
value<0.006 and SNPs with a p-value<0.0002 were considered statistically significant. We ad-
ditionally evaluated whether SNPs associated with vitamin D levels in published GWAS
(rs2282679, rs12785878, rs10741657, rs6013897) on circulating vitamin D [26,27], or represen-
tative tag SNPs, were associated with vitamin D in a subset of our study sample.
Results
Genetic variation in the vitamin D metabolic pathway overall was not associated with risk of
pancreatic cancer (pathway ARTP p-value = 0.830, Table 1). None of the 11 genes were associ-
ated with pancreatic cancer (Table 1). SNPs near the VDR (rs2239186), GC (rs2282679), LRP2
(rs4668123), CYP24A1 (rs2762932), and CUBN (rs1810205) genes were the top SNPs associat-
ed with pancreatic cancer (p-values 0.008–0.037) (Table 2), although they did not reach the
threshold for statistical significance after adjusting for multiple comparisons.
A test for heterogeneity between the three phases of PanScan indicated no evidence of het-
erogeneity after adjustment for multiple comparisons. Results stratified by PanScan phase are
presented for the overall pathway and 11 genes in S4 Table and for SNPs with nominal p-values
<0.05 in S5 Table. No associations were significant after adjustment for multiple comparisons.
In analyses stratified by high vs. low circulating vitamin D concentration, no significant
Vitamin D Genes and Pancreatic Cancer
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Table 1. Pathway analysis for risk of pancreatic cancer and gene sets in the vitamin D pathway (3,583 cases and 7,053 controls)
SNPS (n) Gene/pathway p-valuea Most significant SNP
Total Pathway 213 0.830 rs2239186
Gene
VDR 22 0.116 rs2239186
GC 7 0.186 rs2282679
LRP2 33 0.328 rs4668123
CYP24A1 24 0.401 rs2762932
CYP27B1 3 0.457 rs10877013
CASR 13 0.568 rs7632399
CYP2R1 8 0.699 rs1562902
CYP27A1 5 0.704 rs7566656
DHCR7 4 0.873 rs3750997
RXRA 17 0.760 rs3132294
CUBN 77 0.798 rs1810205
aP-values account for number of SNPs within genes or within the overall pathway, but not for the total number of genes; Models were adjusted for age
(50, 51–60, 61–70, 71–80, 81 years), sex, study and population stratification by 5 eigenvectors for ethnic ancestry.
doi:10.1371/journal.pone.0117574.t001
Table 2. Vitamin-D related single nucleotide polymorphisms (SNPs) with p-values <0.05 and risk of pancreatic cancer from PanScan I-III (3,583
cases and 7,053 controls).




Allelic ORb,c Nominal P-heterogeneity by study
phased
VDR rs2239186 12q13.11 T,C 0.192/0.208 0.008 0.89 (0.82–
0.97)
0.914
rs7967152 12q13.11 C,A 0.460/0.475 0.040 0.93 (0.87–
1.00)
0.500
rs12721364 12q13.11 C,T 0.142/0.152 0.046 0.91 (0.82–
1.00)
0.740
GC rs2282679 4q12-q13 A,C 0.270/0.287 0.036 0.92 (0.86–
0.99)
0.176
LRP2 rs4668123 2q24-q31 C,T 0.250/0.272 0.027 0.90 (0.82–
0.99)
0.002
CYP24A1 rs2762932 20q13 T,C 0.152/0.158 0.034 0.90 (0.82–
0.99)
0.939
CUBN rs1810205 10p12.31 A,G 0.384/0.378 0.037 1.08 (1.00–
1.15)
0.043
rs2356215 10p12.31 C,T 0.111/0.101 0.041 1.12 (1.00–
1.25)
0.754
a After bonferroni correction (0.05/213) p-values < 0.0002 were considered significant
b Odds ratios (ORs) were adjusted for age (50, 51–60, 61–70, 71–80, 81 years), sex, study, and population stratification by 5 eigenvectors for
ethnic ancestry.
c Odds ratios (ORs) are for the number of copies of the minor allele.
d Phase refers to participation in PanScan I, II or III. For rs4668123 data was available only from PanScan phases II and III.
doi:10.1371/journal.pone.0117574.t002
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differences were observed and tests for interaction between vitamin D concentration and each
of the top 20 SNPs were not significant (all p-values> 0.1; data not shown).
Of the four variants identified as associated with circulating vitamin D concentration in
published GWAS [26,27], in our sample only a tag SNP in GC showed an association (p = 5.30
x10–7) with vitamin D status; tag SNPs in or near DHCR7/NADSYN1 and CYP2R1 did not
show an association and rs6013897 in CYP24A1 could not be studied as the Illumina Human-
Hap550 platform does not include a tag SNP for rs6013897.
Discussion
This study is the largest to date to evaluate the joint effects of SNPs in the vitamin D metabolic
pathway and risk of pancreatic cancer. Contrary to our hypothesis that we would observe an as-
sociation between the vitamin D metabolic pathway and risk of pancreatic cancer, we found no
evidence for an association, either for the pathway, genes, individual SNPs, nor for interactions
with measured serum vitamin D concentrations.
The previous study on genetic variants in the vitamin D pathway and pancreatic cancer risk
based in Canada showed significant p-values for SNPs in the CASR, CYP24A1, CYP2R1,
DHCR7, and LRP2 genes (p-values ranged from 0.011–0.050), but after adjustment for multiple
comparisons none of the associations remained significant [13]. Although for different SNPs,
our results showing associations with SNPs in the CYP24A1 and LRP2 regions may offer some
support these findings. The strongest SNP association demonstrated in our study was in the
VDR gene (p-values 0.008–0.046 for three significant SNPs), which was not observed in the
Canadian study.
Research specific to polymorphisms in the vitamin D metabolic pathway and pancreatic
cancer is limited [28]. However, more research exists on the hormonally active form of vitamin
D, calcitriol. Preclinical trials suggest anti-proliferative effects of calcitriol in skin, lymph
nodes, and mammary tissues [29] and pancreatic cancer cells [30], attributed to mechanisms
related to angiogenesis inhibition, G0/G1 cell cycle arrest, differentiation, induction of apopto-
sis and modulating different signaling pathways in tumor cells [1].
Strengths of our study include the very large sample size with genetic data, and the subset
with both genetic data and 25(OH)D measured before diagnosis. Including genes in the path-
way that not only have been shown to predict circulating vitamin D but also those that are
known to be involved in metabolism in a collective pathway provides a broader scope of the bi-
ological process as it might relate to pancreatic cancer risk. Blood concentrations of vitamin D
can vary by season of blood draw or other characteristics such as physical activity or BMI; al-
though we did not have information on dietary and supplemental vitamin D intake, we adjust-
ed for available covariates in the analyses stratified by circulating vitamin D status. Still, genetic
data are less subject to influence or confounding by exogenous exposures. Limitations of our
study include the differences between genotyping platforms, as 17 SNPs in the analysis were
not included in the PanScan I platform. Also, although extensive quality control procedures
were instituted, circulating 25(OH)D was assayed at two different locations, introducing the
potential for batch effects or other variations between labs and measurements.
Conclusion
Our findings do not support an association between common genetic variants in the vitamin D
metabolic pathway and risk of pancreatic cancer, despite the large sample size and ability to as-
sess effect measure modification by circulating vitamin D concentration. Future research
should explore other pathways through which vitamin D might be associated with risk of
Vitamin D Genes and Pancreatic Cancer
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pancreatic cancer; for example through studies of gene-nutrient interactions involving variants
in downstream signaling pathways involving vitamin D.
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